Adaptive Biotechnologies Co. (NASDAQ:ADPT - Get Free Report) saw unusually-strong trading volume on Monday . Approximately 320,388 shares traded hands during trading, a decline of 45% from the previous session's volume of 586,288 shares.The stock last traded at $7.33 and had previously closed at $7.20.
Analysts Set New Price Targets
A number of research analysts have weighed in on ADPT shares. BTIG Research increased their price target on Adaptive Biotechnologies from $8.00 to $9.00 and gave the stock a "buy" rating in a research note on Wednesday, December 18th. Piper Sandler upped their price target on shares of Adaptive Biotechnologies from $6.00 to $7.00 and gave the company an "overweight" rating in a report on Monday, November 11th.
Read Our Latest Stock Analysis on ADPT
Adaptive Biotechnologies Stock Down 2.1 %
The business's 50-day moving average price is $5.87 and its 200-day moving average price is $4.92. The firm has a market capitalization of $1.04 billion, a PE ratio of -5.26 and a beta of 1.47.
Institutional Inflows and Outflows
Hedge funds have recently made changes to their positions in the stock. Bank of New York Mellon Corp grew its stake in shares of Adaptive Biotechnologies by 16.4% in the second quarter. Bank of New York Mellon Corp now owns 460,132 shares of the company's stock worth $1,666,000 after acquiring an additional 64,788 shares during the last quarter. Rhumbline Advisers grew its holdings in shares of Adaptive Biotechnologies by 8.3% in the 2nd quarter. Rhumbline Advisers now owns 188,285 shares of the company's stock worth $682,000 after purchasing an additional 14,430 shares during the last quarter. Los Angeles Capital Management LLC increased its holdings in shares of Adaptive Biotechnologies by 104.1% during the second quarter. Los Angeles Capital Management LLC now owns 44,159 shares of the company's stock worth $160,000 after buying an additional 22,527 shares in the last quarter. American Century Companies Inc. boosted its holdings in shares of Adaptive Biotechnologies by 18.3% in the 2nd quarter. American Century Companies Inc. now owns 45,562 shares of the company's stock worth $165,000 after acquiring an additional 7,039 shares in the last quarter. Finally, Massachusetts Financial Services Co. MA increased its holdings in Adaptive Biotechnologies by 50.9% during the 2nd quarter. Massachusetts Financial Services Co. MA now owns 3,912,027 shares of the company's stock valued at $14,162,000 after purchasing an additional 1,319,709 shares in the last quarter. Institutional investors and hedge funds own 99.17% of the company's stock.
About Adaptive Biotechnologies
(
Get Free Report)
Adaptive Biotechnologies Corporation, a commercial-stage company, develops an immune medicine platform for the diagnosis and treatment of various diseases. The company offers immunosequencing platform which combines a suite of proprietary chemistry, computational biology, and machine learning to generate clinical immunomics data to decode the adaptive immune system.
Featured Articles
Before you consider Adaptive Biotechnologies, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Adaptive Biotechnologies wasn't on the list.
While Adaptive Biotechnologies currently has a "Moderate Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Wondering what the next stocks will be that hit it big, with solid fundamentals? Enter your email address to see which stocks MarketBeat analysts could become the next blockbuster growth stocks.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
